This case report examined eight members of a Chinese family to understand the effects of an APOA5 variant known as p.R223C. The team compared those carrying the genetic change with family members who did not carry it. They found that individuals with the variant had substantially higher fasting plasma triglyceride levels than the admitted threshold of 1.7 mmol/L. Among the six carriers, five had elevated triglycerides, while the single non-carrier had normal levels. One carrier reached a peak level of 4.96 mmol/L. The genetic change was classified as Likely Pathogenic according to ACMG/AMP guidelines. The report notes that preliminary in silico verification was used. No adverse events or safety concerns were reported because this was a case report without a control group or intervention. Readers should be cautious because rare genetic variants observed in isolated cases are often difficult to establish conclusively. The real effect of this variant requires further investigation via biochemical or cell-based studies. This preliminary finding does not change current medical practice yet.
APOA5 p.R223C variant linked to substantially higher fasting triglycerides in a Chinese familyLikely Pathogenic APOA5 Variant Linked to High Triglycerides in Chinese Family
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This guideline presents a case report of a Chinese family with an APOA5 p.R223C variant. The scope is to report triglyceride levels in carriers versus a non-carrier family member. The main finding is that fasting plasma triglyceride levels were substantially higher in variant carriers than the admitted threshold of 1.7 mmol/L. Six carriers had elevated triglycerides, while one non-carrier had normal triglycerides. The highest fasting triglyceride level reported was 4.96 mmol/L. The authors classify the variant as Likely Pathogenic according to ACMG/AMP guidelines but note preliminary in silico verification. A key limitation is that the real effect of this variant requires further investigation via biochemical or cell-based studies. The authors also note that rare APOA5 variants observed only in isolated cases are often difficult to establish conclusively. Practice relevance was not reported, and the findings are preliminary.